Healthcare - Biotechnology - NASDAQ - US
$ 0.5683
9.2 %
$ 23.2 M
Market Cap
-0.16
P/E
INCOME STATEMENT
1.38 M
REVENUE
-168 M
OPERATING INCOME
-179 M
NET INCOME
EFFICIENCY
Earnings Waterfall
BioXcel Therapeutics, Inc.
| Revenue | 1.38 M |
| Cost Of Revenue | 1.26 M |
| Gross Profit | 120 K |
| Operating Expenses | 172 M |
| Operating Income | -168 M |
| Other Expenses | 11.4 M |
| Net Income | -179 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 1.4 | 0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 1.3 | 20 K | 0.3 | 0.2 | 0.2 | 17 K | 1 K | 0 | 0 |
| Gross Profit | 0.1 | 0.4 | (0.3) | (0.2) | (0.2) | 17 K | 1 K | 0 | 0 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 171.9 | 160.0 | 106.9 | 82.3 | 33.6 | 20.0 | 4.5 | 2.1 | 0.6 |
| Selling, General and Administrative Expenses | 83.4 | 68.8 | 54.2 | 24.3 | 7.8 | 5.4 | 1.8 | 0.7 | 0.4 |
| Research and Development Expenses | 84.3 | 91.2 | 52.7 | 58.0 | 25.8 | 14.6 | 2.7 | 1.4 | 0.2 |
| Operating Income | (167.6) | (159.6) | (106.9) | (82.3) | (33.6) | (20.0) | (4.5) | (2.1) | (0.6) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 13.3 | 8.2 | 40 K | 27 K | 0 | 0 | 2 K | 0 | 0 |
| Total Other Income | (11.4) | (6.1) | (0.4) | 0.1 | 0.6 | 0.7 | 2 K | 0 | 0 |
| Pre-Tax Income | (179.1) | (165.8) | (106.9) | (82.2) | (33.0) | (19.3) | (4.5) | (2.1) | (0.6) |
| NET INCOME | |||||||||
| Tax Provision | 0 | 6.1 | (0.3) | (0.2) | (0.6) | 0.7 | 0 | (2.1) | 0 |
| Net Income | (179.1) | (171.8) | (106.6) | (82.0) | (32.3) | (19.3) | (4.5) | (2.1) | (0.6) |
| EPS | 6.15 | 6.13 | 4.04 | 3.78 | 1.99 | 1.32 | 0.3 | 0.14 | 0.0399 |